Journal profile · INFECTIOUS DISEASES
AIDS Research and Therapy
ISSN 1742-6405 · BioMed Central · ENGLAND · Founded 2004
AIDS Research and Therapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.72; fully open access; APC about USD 3,090; median 104 days to acceptance (107 articles, last 24 months); 141 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
AIDS Research and Therapy is published by BioMed Central and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are HIV/AIDS Research and Interventions, HIV Research and Treatment and HIV/AIDS drug development and treatment, together about 56.3% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
AIDS Research and Therapy publishes studies of basic, translational, clinical, epidemiological, behavioral and educational science addressing treatment and prevention of HIV/AIDS and associated conditions. This includes studies of disease pathogenesis, novel treatment strategies and the impacts of established treatment regimans.
From the journal's Aims & Scope
Research area (LetPub): INFECTIOUS DISEASES
Editor-in-chief Barbara CastelnuovoPublisher website
Editorial board by country: none in mainland China; most named United States 25, Australia 11, Canada 5, United Kingdom 3, India 3 (67 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- HIV/AIDS Research and InterventionsMedicine24.9%
- HIV Research and TreatmentImmunology and Microbiology15.8%
- HIV/AIDS drug development and treatmentMedicine15.6%
- HIV-related health complications and treatmentsMedicine12.4%
- Adolescent Sexual and Reproductive HealthHealth Professions5.5%
- HIV, Drug Use, Sexual RiskMedicine3.3%
- Pneumocystis jirovecii pneumonia detection and treatmentMedicine3.1%
- Biological Research and Disease StudiesBiochemistry, Genetics and Molecular Biology1.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Infectious Diseases | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASCAB AbstractsPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.72LetPub ·
- Impact factor (publisher) 2025
- 2.8Publisher website ·
- 5-year impact factor (publisher) 2025
- 3.1Publisher website ·
- CiteScore 2026-06
- 3.8LetPub ·
- SJR 2026-06
- 0.93LetPub ·
- SNIP 2026-06
- 1.04LetPub ·
- h-index
- 35LetPub ·
- h-index
- 68OpenAlex ·
- i10-index
- 590OpenAlex ·
- 2-year mean citedness
- 2.36OpenAlex ·
- Self-citation rate
- 7.1%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 136LetPub ·
- Articles per year (publisher)
- 2,025Publisher website ·
- Downloads per year (publisher) 2025
- 888,400Publisher website ·
Articles by year OpenAlex count · 1,227 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 109 | 109 | 17 |
| 2025 | 141 | 141 | 333 |
| 2024 | 102 | 102 | 479 |
| 2023 | 91 | 91 | 990 |
| 2022 | 69 | 69 | 1,034 |
| 2021 | 100 | 100 | 1,799 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
104 daysMedian, submission to acceptance · P25–P75 65 days – 151 days
- Acceptance to online
- median 26 days (109 articles)
- Submission to online
- median 130 days
- Sample
- 107 articles with submission and acceptance dates (288 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Submission to first decision
- 6 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Unspecified peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 2,590 / USD 3,090 / GBP 2,190 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 2,990 / EUR 2,490 / GBP 2,090 | — | — | |
| LetPub | GBP 1,990 / USD 2,890 / EUR 2,390 | Yes | — | |
| Publisher website | GBP 2,190 / USD 3,090 / EUR 2,590 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers2, by deadline
Publisher websiteArticle types accepted6
- brief communicationResearch Case report Hypothesis Methodology Review Brief CommunicationLength not stated
- case reportResearch Case report Hypothesis Methodology Review Brief CommunicationLength not stated
- hypothesisResearch Case report Hypothesis Methodology Review Brief CommunicationLength not stated
- methodologyResearch Case report Hypothesis Methodology Review Brief CommunicationLength not stated
- researchResearch Case report Hypothesis Methodology Review Brief CommunicationLength not stated
- reviewResearch Case report Hypothesis Methodology Review Brief CommunicationLength not stated
Policy excerpts from the journal's websiteAuthorship, Data availability, License & copyright, Open access, Peer review
- Authorship
Submission restricted to authors; third-party submissions not allowed. Model summary
Please note that a manuscript can only be submitted by an author of the manuscript and may not be submitted by a third party.
Source ↗Publisher website ·- Data availability Formatting the 'Availability of data and materials' section of your manuscript
Data sharing: strongly encouraged or required; deposit in public repositories where appropriate; data availability statement required. Model summary
The following format for the 'Availability of data and materials section of your manuscript should be used:
Source ↗Publisher website ·- License & copyright Licensing and copyright
Open access licensing: CC BY-NC-ND 4.0 or CC BY 4.0. Model summary
Creative Commons licences Open access articles in Springer Nature journals are published under Creative Commons licences. These provide an industry-standard framework to support easy re-use of open access material. Under Creative Commons licences, authors retain copyright of their articles. AIDS Research and Therapy articles are published open access under a CC BY-NC-ND (Creative Commons Attributi…
Source ↗Publisher website ·- Open access Benefits of open access
Publishing open access (OA) offers a number of benefits, including greater reach and readership for your work: Cited more 1.6x more citations of OA articles than non-OA articles across all subjects Downloaded more 4x more downloads of OA articles than non-OA articles Greater impact 2.5x more Altmetric attention. OA articles attracted 1.9x more news mentions and 1.2x more policy mentions Open acces…
Source ↗Publisher website ·- Peer review Peer review policy
Peer review is the process used to evaluate the quality of a manuscript before publication. Independent researchers in the relevant field assess submitted manuscripts to check their validity and robustness. Their feedback guides editors in making publication decisions. Typically, two or more experts evaluate each manuscript based on three main criteria: scientific robustness: is the research metho…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- ENGLAND
- Language
- English
- Founded
- 2004
- ISSN
- 1742-6405
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about AIDS Research and Therapy
What CAS zone is AIDS Research and Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, AIDS Research and Therapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Infectious Diseases. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of AIDS Research and Therapy?
The latest impact factor listed by LetPub is 2.72; CiteScore 3.8, h-index 68.
How long does peer review take at AIDS Research and Therapy?
Based on the dates recorded on 107 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 104 days (interquartile range 65–151 days); authors report an average review time of about 16 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of AIDS Research and Therapy based?
Of the 67 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (25), Australia (11) and Canada (5). Counted from the institutions listed on the board page; for reference only.
Which databases index AIDS Research and Therapy?
According to LetPub and DOAJ records, AIDS Research and Therapy is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase, CAS and CAB Abstracts; that list has not been checked against each database.
Is AIDS Research and Therapy open access, and what is the APC?
AIDS Research and Therapy is a fully open-access journal. APC about USD 3,090.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .